Portfolio Grader currently ranks GlaxoSmithKline Plc (NYSE:GSK) a Hold. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. The shares have been upgraded from a Sell to a Hold in the last week.

GlaxoSmithKline Plc (NYSE:GSK) is a constituent of the 133 company Pharmaceuticals GICS industry group, which is part of the 781 company GICS Health Care sector. GSK has a market value of $85.7 billion which is in the top 10% of its industry group. The ranking for GSK by Portfolio Grader places it 87 among the 133 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 503 among the 781 companies in the sector, and number 3,192 in the nearly 5,000 company Portfolio Grader universe.

GlaxoSmithKline Plc (NYSE:GSK) is one of 132 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 782 company GICS Health Care sector. GSK's market value is $86.3 billion which places it in the top decile in its industry group. The ranking for GSK by Portfolio Grader places it 88 among the 132 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 511 among the 782 companies in the sector, and number 3,219 in the nearly 5,000 company Portfolio Grader universe.

GlaxoSmithKline Plc (NYSE:GSK) is a $88.4 billion in market value constituent of the Pharmaceuticals GICS industry group where The current Portfolio Grader ranking for GSK puts it 77 among the 133 companies in this industry group, giving it a below-average spot. GSK is ranked in the third quartile of the sector with a ranking of 499 among the 785 companies in the sector and number 3,205 in the 5000 company Portfolio Grader company universe.

Portfolio Grader currently ranks GlaxoSmithKline Plc (NYSE:GSK) a Sell. The methodology for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.

The current recommendation of Hold for GlaxoSmithKline Plc (NYSE:GSK) is computed using the methodology for investing of Louis Navellier and his Portfolio Grader stock evaluator. GSK has recently seen its Portfolio Grader rating upgraded from a Sell to a Hold.

GlaxoSmithKline Plc (NYSE:GSK) is ranked as a Hold using the system of Louis Navellier for investing and his Portfolio Grader stock evaluator. GSK has been upgraded from a Sell to a Hold in the last week.

Currently, GlaxoSmithKline Plc (NYSE:GSK) has a Sell using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. GSK has maintained this ranking for 2 months.